Therapy with drugs containing the active ingredient LOMITAPIDE in patients with homozygous form of familial hypercholesterolemia: a statement of the committee of the Czech Society for Atherosclerosis


Authors: Vladimír Bláha 1;  Michal Vrablík 2;  Vladimír Soška 3;  Jan Piťha 4;  Renata Cífková 5;  Tomáš Freiberger 6;  David Karásek 7;  Pavel Kraml 8;  Hana Rosolová 9;  Tomáš Štulc 2;  Zuzana Urbanová Za Výbor Čsat 10
Authors‘ workplace: III. interní gerontometabolická klinika LF UK a FN Hradec Králové 1;  Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze 10;  III. interní klinika 1. LF UK a VFN v Praze 2;  Oddělení klinické biochemie, II. interní klinika LF MU a FN u sv. Anny v Brně 3;  Interní klinika 2. LF UK a FN Motol a Laboratoř pro výzkum aterosklerózy IKEM, Praha 4;  Centrum kardiovaskulární prevence 1. LF UK a Thomayerova nemocnice, Praha 5;  Centrum kardiovaskulární a transplantační chirurgie, Brno 6;  III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc 7;  II. interní klinika 3. LF a FN Královské Vinohrady, Praha 8;  II. interní klinika LF UK a FN Plzeň 9
Published in: AtheroRev 2020; 5(2): 76-82
Category: Guidelines


Sources
  1. Vaclová M, Vrablík M. Novinky o familiární hypercholesterolemii pro kardiology. Kardiol Rev Int Med 2019; 21(2): 60–64.
  2. Thompson GR, Barbir M, Davies D et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208(2): 317–321. Dostupné z DOI: <https://doi.org/10.1016/j.atherosclerosis.2009.06.010>.
  3. Cuchel M, Bruckert E, Ginsberg HN et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35(32): 2146–2157. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu274>.
  4. France M, Rees A, Datta D et al. [HEART UK Medical Scientific and Research Committee]. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis 2016; 255: 128–139. Dostupné z DOI: <https://doi.org/10.1016/j.atherosclerosis.2016.10.017>.
  5. Freiberger T, Vaclová M, Tichý L et al. Familiární hypercholesterolemie v České republice v roce 2016. Vnitř Lék 2016; 62(11): 924–928.
  6. Alonso R, Díaz-Díaz JL, Arrieta F et al. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. J Clin Lipidol 2016; 10(4): 953–961. Dostupné z DOI: <https://doi.org/10.1016/j.jacl.2016.04.006>.
  7. Sánchez-Hernández RM, Civeira F, Stef M et al. Homozygous Familial Hypercholesterolemia in Spain. Circ Cardiovasc Genet 2016; 9(6): 504–510. Dostupné z DOI: <https://doi.org/10.1161/CIRCGENETICS.116.001545>.
  8. LOJUXTA. SPC. European Medicines Agency (EMA). Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/lojuxta-epar-product-information_en.pdf>.
  9. Blom DJ, Averna MR, Meagher EA et al. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients with Homozygous Familial Hypercholesterolemia. Circulation 2017; 136(3): 332–335. Dostupné z DOI: <https://doi.org/10.1161/CIRCULATIONAHA.117.028208>.
  10. Blom DJ, Cuchel M, Ager M et al. Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia. Orphanet J Rare Dis 2018; 13(1): 96. Dostupné z DOI: <https://doi.org/10.1186/s13023–018–0841–3>.
  11. Græsdal A, Bogsrud MP, Holven KB et al. Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol 2012; 6(4): 331–339. Dostupné z DOI: <https://doi.org/10.1016/j.jacl.2012.03.004>.
  12. Kayikcioglu M, Tokgozoglu L, Yilmaz M et al. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). Atherosclerosis 2018; 270: 42–48. Dostupné z DOI: <https://doi.org/10.1016/j.atherosclerosis.2018.01.034>.
  13. D’Erasmo L, Cefalù AB, Noto D et al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy. Adv Ther 2017; 34(5): 1200–1210. Dostupné z DOI: <https://doi.org/10.1007/s12325–017–0531-x>.
  14. Kolovou G, Diakoumakou O, Kolovou V et al. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol 2020; 27(2): 157–165. Dostupné z DOI: <https://doi.org/10.1177/2047487319870007>.
  15. Cuchel M, Meagher EA, du Toit Theron HE et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381(9860): 40–46. Dostupné z DOI: <https://doi.org/10.1016/S0140–6736(12)61731–0>.
  16. A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH). Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT00730236>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults

Article was published in

Athero Review

Issue 2

2020 Issue 2

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account